Diagnosing Your Cyst: Imaging, Blood Tests, and Pathology
At a Glance
An ovarian cystadenoma is assessed using ultrasound, sometimes MRI, and blood tests such as CA-125, but these tests estimate risk rather than prove the diagnosis. Microscopic examination of tissue removed during surgery provides the definitive diagnosis.
Diagnosing an ovarian cystadenoma is a multi-step process. Because imaging alone cannot look at cells under a microscope, your care team uses a combination of specialized ultrasound, blood tests, and occasionally MRI to estimate the risk that a cyst is benign [1]. The only way to confirm a diagnosis with 100% certainty is through a histopathologic examination—analyzing the tissue after it has been surgically removed [2][1].
The Role of Imaging
Imaging is the first line of defense. Radiologists look for specific “reassuring” features that suggest a cyst is a benign cystadenoma rather than something more serious.
Ultrasound: The First Look
Ultrasound is the most common tool for evaluating ovarian cysts. To help doctors speak the same language, they use standardized risk-classification systems like IOTA (International Ovarian Tumor Analysis) or O-RADS (Ovarian-Adnexal Reporting and Data System) for ultrasound [3][4]. Remember that an O-RADS score is a risk category, not a final histologic diagnosis.
- Reassuring Features: A suspected benign serous cystadenoma often appears as a unilocular cyst—a single, smooth-walled sac filled with clear fluid [5]. It should have no solid components (firm tissue) or mural nodules (bumps on the inside wall) [5].
- The “Honeycomb” Appearance: A suspected mucinous cystadenoma is more likely to be multilocular, meaning it looks like a cluster of many small fluid-filled pockets separated by thin walls (septa) [6][7].
- Concerning Features: Doctors become more concerned if they see papillary projections (small finger-like growths) that have their own blood flow, or if the cyst walls are thick and irregular [8][9]. If these are present, you may need a gynecologic-oncology assessment.
MRI: The “Problem Solver”
If an ultrasound is “indeterminate” (unclear), your doctor may order an MRI. MRI is excellent at identifying whether a structure inside a cyst is truly solid tissue or just thick fluid [10].
- Stained-Glass Appearance: On MRI, mucinous cystadenomas often show a “stained-glass” pattern, where different pockets of the cyst have different colors because the fluid (mucin) inside them has different thicknesses [11].
- O-RADS MRI Score: Radiologists also use an MRI version of the O-RADS scale (1 to 5). A score of 2 or 3 generally indicates a very low risk of malignancy, while scores of 4 or 5 require more intensive follow-up or surgical intervention [12].
Understanding Tumor Markers (CA-125)
You may be given a blood test for CA-125, a protein that can be elevated in the presence of ovarian cancer. However, it is a limited tool and must be interpreted carefully [2].
- It is not a “Cancer Test”: CA-125 is not specific to cancer. It can be elevated by many benign conditions, including endometriosis, uterine fibroids, menstruation, or even a simple infection [2][13].
- Context Matters: In one specific study cohort, about 89% of women with benign ovarian tumors had a normal CA-125 level (below 35 U/mL) [14]. However, this statistic alone does not rule cancer in or out.
- When it’s Helpful: Doctors use CA-125 alongside your menopausal status and imaging to help calculate a “Risk of Malignancy Index” (RMI). It is more reliable in postmenopausal women, as premenopausal women have many more natural reasons for the protein to fluctuate [15].
Your Pathology Report
After surgery, a pathologist examines the cyst under a microscope. This integrated report is the “gold standard” for your diagnosis.
A benign report generally describes the overall architecture and cellular details of the cyst. While pathologists evaluate the whole picture rather than relying on a rigid checklist, examples of what they look for include:
| Feature | Examples of Reassuring Terminology | Why it matters |
|---|---|---|
| Cell Lining | “Single layer of columnar or cuboidal cells” [16][17] | Confirms the cells are organized and not piling up excessively. |
| Atypia | “Absence of cytologic atypia” [18] | “Atypia” means the cells look abnormal or “angry”. |
| Invasion | “No evidence of destructive stromal invasion” [19] | This is crucial; it confirms the cells are not “eating into” the ovary tissue. |
| Complexity | “Smooth lining” or “Simple architecture” | Shows the cyst does not have the highly complex, branching patterns seen in borderline tumors [20]. |
Do Not Self-Diagnose: It is important not to self-interpret isolated words. Benign lesions can occasionally show some complex architecture or occasional mitoses. If your report uses terms like stratification (more than 2-3 layers of cells) or nuclear pleomorphism, these are features that might lean toward a borderline tumor rather than a simple benign cystadenoma, but they must be interpreted in context by your specialist [21]. Always ask your treating clinician to explain the final integrated diagnosis.
Common questions in this guide
Can an ultrasound confirm that an ovarian cyst is a cystadenoma?
What does an O-RADS score mean for an ovarian cyst?
Why might my doctor order an MRI after an ultrasound?
Does a high CA-125 level mean I have ovarian cancer?
What confirms an ovarian cystadenoma diagnosis after surgery?
Which pathology terms might raise concern for a borderline ovarian tumor?
Get notified when new evidence is published on ovarian cystadenoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Clinicomorphological Spectrum of Ovarian Cystic Lesions.
Dhakal R, Makaju R, Bastakoti R
Kathmandu University medical journal (KUMJ) 2016; (14(53)):13-16.
PMID: 27892434 - 2
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016; (26(1)):43-51 doi:10.1097/IGC.0000000000000586.
PMID: 26588231 - 3
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.
Timmerman D, Van Calster B, Testa A, et al.
American journal of obstetrics and gynecology 2016; (214(4)):424-437 doi:10.1016/j.ajog.2016.01.007.
PMID: 26800772 - 4
External validation of ultrasound-based models for differentiating between benign and malignant adnexal masses: a nationwide prospective multicenter study (IOTA phase 6).
Moro F, Momi M, Ledger A, et al.
American journal of obstetrics and gynecology 2025; (233(6)):629.e1-629.e13 doi:10.1016/j.ajog.2025.07.017.
PMID: 40653066 - 5
Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice.
Ohya A, Fujinaga Y
Japanese journal of radiology 2022; (40(12)):1213-1234 doi:10.1007/s11604-022-01321-x.
PMID: 35916971 - 6
The Coexistence of Two Different Epithelial Ovarian Tumors: A Rare Case.
Topaloğlu ÖF, Uysal E, Çelik ZE, Çelik Ç
Current medical imaging 2022; (18(4)):421-424 doi:10.2174/1573405617666210908125237.
PMID: 34503421 - 7
A Nomogram Combined Radiomic and Semantic Features as Imaging Biomarker for Classification of Ovarian Cystadenomas.
Pan S, Ding Z, Zhang L, et al.
Frontiers in oncology 2020; (10()):895 doi:10.3389/fonc.2020.00895.
PMID: 32547958 - 8
Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses.
Velayo CL, Reforma KN, Sicam RVG, et al.
Healthcare (Basel, Switzerland) 2022; (11(1)) doi:10.3390/healthcare11010008.
PMID: 36611467 - 9
Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules.
Abramowicz JS, Timmerman D
American journal of obstetrics and gynecology 2017; (217(6)):652-660 doi:10.1016/j.ajog.2017.07.019.
PMID: 28735703 - 10
Ovarian-Adnexal Reporting Data System Magnetic Resonance Imaging (O-RADS MRI) Score for Risk Stratification of Sonographically Indeterminate Adnexal Masses.
Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, et al.
JAMA network open 2020; (3(1)):e1919896 doi:10.1001/jamanetworkopen.2019.19896.
PMID: 31977064 - 11
Postmenopausal adnexal torsion: rare case report.
Abdelazim IA, AbuFaza M, Bekmukhambetov Y, et al.
Przeglad menopauzalny = Menopause review 2020; (19(1)):49-51 doi:10.5114/pm.2020.95295.
PMID: 32699544 - 12
O-RADS MRI SCORE: An Essential First-Step Tool for the Characterization of Adnexal Masses.
Thomassin-Naggara I, Dabi Y, Florin M, et al.
Journal of magnetic resonance imaging : JMRI 2024; (59(3)):720-736 doi:10.1002/jmri.28947.
PMID: 37550825 - 13
Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.
Dochez V, Caillon H, Vaucel E, et al.
Journal of ovarian research 2019; (12(1)):28 doi:10.1186/s13048-019-0503-7.
PMID: 30917847 - 14
Clinicopathological Spectrum of Ovarian Tumors and Diagnostic Utility of Cancer Antigen 125 (CA-125): An Observational Study From Eastern India.
Choudhary A, Paswan MK, Jamaiyar A
Cureus 2026; (18(6)):e111404 doi:10.7759/cureus.111404.
PMID: 42500789 - 15
Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
Al Musalhi K, Al Kindi M, Al Aisary F, et al.
Oman medical journal 2016; (31(5)):336-44 doi:10.5001/omj.2016.68.
PMID: 27602187 - 16
Giant Benign Ovarian Serous Cystadenoma in a Postmenopausal Woman.
Mpourazanis G, Ntanasis A, Aliri M, et al.
Cureus 2026; (18(5)):e108828 doi:10.7759/cureus.108828.
PMID: 42291944 - 17
Rare association of epidermoid cyst of ovary with mucinous cystadenoma- A Case Report.
Qayoom Z, Yaqoob N
JPMA. The Journal of the Pakistan Medical Association 2023; (73(5)):1108-1110 doi:10.47391/JPMA.5635.
PMID: 37218245 - 18
Pathology of borderline and invasive cancers.
Prat J
Best practice & research. Clinical obstetrics & gynaecology 2017; (41()):15-30 doi:10.1016/j.bpobgyn.2016.08.007.
PMID: 28277307 - 19
Lymph Node Involvement in Recurrent Serous Borderline Ovarian Tumors: Current Evidence, Controversies, and a Review of the Literature.
Wetterwald L, Sarivalasis A, Liapi A, et al.
Cancers 2023; (15(3)) doi:10.3390/cancers15030890.
PMID: 36765848 - 20
MRI of Borderline Epithelial Ovarian Tumors: Pathologic Correlation and Diagnostic Challenges.
Tsuboyama T, Sato K, Ota T, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2022; (42(7)):2095-2111 doi:10.1148/rg.220068.
PMID: 36083804 - 21
Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.
Avril S
Der Pathologe 2017; (38(Suppl 2)):180-191 doi:10.1007/s00292-017-0375-9.
PMID: 29119232
This page explains how ovarian cystadenomas are evaluated for informational purposes only and does not constitute medical advice. Your gynecologist, radiologist, and pathologist should interpret your imaging, blood tests, and pathology together.